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Abstract
Objective: To compare two models of pulmonary hypertension (monocrotaline and monocrotaline+pneumonectomy) 
regarding hemodynamic severity, structure of pulmonary arteries, inflammatory markers (IL-1 and PDGF), and 
45-day survival. Methods: We used 80 Sprague-Dawley rats in two study protocols: structural analysis; and 
survival analysis. The rats were divided into four groups: control; monocrotaline (M), pneumonectomy (P), and 
monocrotaline+pneumonectomy (M+P). In the structural analysis protocol, 40 rats (10/group) were catheterized 
for the determination of hemodynamic variables, followed by euthanasia for the removal of heart and lung 
tissue. The right ventricle (RV) was dissected from the interventricular septum (IS), and the ratio between RV 
weight and the weight of the left ventricle (LV) plus IS (RV/LV+IS) was taken as the index of RV hypertrophy. In 
lung tissues, we performed histological analyses, as well as using ELISA to determine IL-1 and PDGF levels. In 
the survival protocol, 40 animals (10/group) were followed for 45 days. Results: The M and M+P rats developed 
pulmonary hypertension, whereas the control and P rats did not. The RV/LV+IS ratio was significantly higher 
in M+P rats than in M rats, as well as being significantly higher in M and M+P rats than in control and P rats. 
There were no significant differences between the M and M+P rats regarding the area of the medial layer of 
the pulmonary arteries; IL-1 and PDGF levels; or survival. Conclusions: On the basis of our results, we cannot 
conclude that the monocrotaline+pneumonectomy model is superior to the monocrotaline model.
Keywords: Monocrotaline; Hypertension, pulmonary; Pneumonectomy; Interleukin-1; Receptor, platelet-
derived growth factor beta.
Resumo
Objetivo: Comparar dois modelos de hipertensão pulmonar (monocrotalina e monocrotalina+pneumonectomia) 
em relação à gravidade hemodinâmica, estrutura de artérias pulmonares, marcadores inflamatórios (IL-1 e PDGF) 
e sobrevida em 45 dias. Métodos: Foram utilizados 80 ratos Sprague-Dawley em dois protocolos de estudo: 
análise estrutural e de sobrevida. Os animais foram divididos em quatro grupos: controle, monocrotalina (M), 
pneumonectomia (P) e monocrotalina+pneumonectomia (M+P). Para a análise estrutural, 40 animais (10/grupo) 
foram cateterizados após 28 dias para a medição dos valores hemodinâmicos e sacrificados, obtendo-se tecidos 
cardíaco e pulmonar. O ventrículo direito (VD) foi dissecado do septo interventricular (SI), e a relação do peso 
do VD e do peso do ventrículo esquerdo (VE) com o SI foi obtida como índice de hipertrofia de VD. No tecido 
pulmonar, foram realizadas análises histológicas e dosados IL-1 e PDGF por ELISA. Para o estudo de sobrevida, 
40 animais (10/grupo) foram observados por 45 dias. Resultados: Os grupos M e M+P apresentaram hipertensão 
pulmonar em relação aos demais. Houve um aumento significativo da relação VD/VE+S no grupo M+P em 
relação aos demais. Não houve diferenças significativas entre os grupos M e M+P quanto à área da camada 
média das artérias pulmonares, dosagens de IL-1 e PDGF ou sobrevida. Conclusões: Baseados nos resultados, 
não podemos afirmar que o modelo de monocrotalina+pneumonectomia é superior ao modelo de monocrotalina.
Descritores: Monocrotalina; Hipertensão pulmonar; Pneumonectomia; Interleucina-1; Receptor beta de fator 
de crescimento derivado de plaquetas.
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marked mononuclear vasculitis in intra-acinar 
arteries and veins.(14) Therefore, after monocrotaline 
causes an intense inflammatory reaction in the 
pulmonary arteries and arterioles, the process 
of vascular remodeling, mainly associated with 
medial thickening, begins.(15,16) These findings 
have led various authors to study the effect of 
monocrotaline on the rat pulmonary circulation and 
its association with different interventions.(9-11,17-20)
Because of its simplicity, the monocrotaline 
model is widely used for testing new drugs; 
however, the list of drugs that can reverse 
monocrotaline-induced PAH is extensive, 
paradoxically including drugs that can cause 
PAH in humans.(21) Therefore, the problem with 
this model is that it does not reliably represent 
all of the changes that occur in human PAH, 
especially because there is no significant endothelial 
proliferation.(7)
Studies conducted more recently have addressed 
the hypothesis that the use of a systemic-
pulmonary shunt or pneumonectomy—producing an 
increase in pulmonary blood flow—in combination 
with the administration of monocrotaline can 
lead to exacerbation of the resulting findings in 
the pulmonary circulation.(22-24) Although such 
studies have suggested that the model combining 
monocrotaline and increased blood flow is superior, 
no direct comparisons have been made in order 
to set the standard for use in future studies. 
Therefore, the objective of the present study was 
to compare the monocrotaline model with the 
model combining monocrotaline and increased 
blood flow (following left pneumonectomy) in 
adult rats, in terms of hemodynamic severity, 
structural changes in the pulmonary arteries, 
inflammatory markers, and 45-day survival.
Methods
All animals were handled humanely, in 
accordance with international standards for 
animal care.(25) The study was approved by the 
Research Ethics Committee of the University of 
São Paulo School of Medicine, located in the 
city of São Paulo, Brazil.
Two study protocols were performed: one for 
structural analysis and one for survival analysis. 
Each protocol included 40 Sprague-Dawley rats 
(weight, 250-300 g) divided into four groups: the 
control group, in which the animals were given a 
subcutaneous injection of saline (1 mL/kg) at the 
study outset (D0); the monocrotaline (M) group, 
Introduction
Pulmonary arterial hypertension (PAH) comprises 
a group of diseases that share pathological 
similarities but differ in pathophysiology and 
prognosis.(1) Clinically, PAH is characterized by 
symptoms of dyspnea, chest pain, and syncope, 
causing progressive limitation, right heart failure, 
and death.(2,3) Idiopathic PAH is rare, has a peak 
incidence in the fourth decade of life, and mainly 
affects females; however, other forms of PAH, 
such as schistosomiasis-associated PAH, are 
potentially more prevalent and can become a 
public health problem.(1,4,5)
According to the 4th World Symposium 
on Pulmonary Hypertension,(6) held in Dana 
Point, CA, USA, PAH is defined by right heart 
catheterization measurements. Therefore, in a 
patient with PAH, cardiac catheterization should 
show a mean pulmonary artery pressure (mPAP) 
≥ 25 mmHg and a pulmonary artery occlusion 
pressure ≥ 15 mmHg.
The disease is the result of complex changes 
that lead to structural modifications in pulmonary 
arteries and arterioles. These changes ultimately 
cause the clinical manifestations of PAH. The 
progression of vascular changes usually occurs 
after one or more offending stimuli in a susceptible 
individual, and, despite the drugs available for 
treatment, PAH remains a fatal disease.(7,8)
Experimental models of PAH have allowed the 
development of all of the therapeutic alternatives 
that are currently available, and the monocrotaline 
model remains the most widely used.(9-11) The use 
of seeds of Crotalaria spectabilis, the plant from 
which monocrotaline is derived, was described 
more than 40 years ago. Initially, the animals 
were fed the seeds, subsequently developing 
PAH.(12) Currently, monocrotaline is administered 
subcutaneously; after undergoing oxidation in 
the liver, monocrotaline produces its pyrrole 
metabolite and reaches the lung, where it causes 
lesions in the pulmonary circulation, the targets 
being various proteins and peptides of the vascular 
endothelium.(13)
Four hours after the substance is administered, 
it is possible to see a relative increase in the 
media of intra-acinar pulmonary arteries, which 
is due to muscle contraction. Within 8-16 h 
after administration, mononuclear inflammatory 
infiltrates are seen in the adventitia of arteries and 
veins, resulting in vasculitis. After approximately 
22 days, there is right ventricular hypertrophy and 
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(abdominal aortic bleeding) and removal of heart 
and lung tissue.
The hemodynamic measurements were 
performed by inserting an umbilical catheter 
into the external jugular vein, the catheter 
being connected to a pressure transducer (HP 
1295C; Hewlett-Packard, Palo Alto, CA, USA) 
coupled to a hemodynamic monitor (Monitox 
Dx 2020; Hewlett-Packard), in accordance with 
a previously described technique.(26) The mPAP 
was thus measured.
The right ventricle (RV) was dissected from the 
left ventricle (LV), the interventricular septum (IS) 
having remained attached to the LV. The ratio 
between RV weight and LV+IS weight was taken 
as the index of right ventricular hypertrophy.(19)
To investigate the degree of inflammation, 
we determined IL-1 and PDGF levels. To measure 
peptide levels, we used a capture ELISA with a 
commercial kit including anti-mouse IL-1 and 
PDGF (R&D System Inc., Minneapolis, MN, USA).
(27) Peptide levels were measured in frozen lung 
samples.
We employed 96-well plates (Costar; Corning 
Inc., Cambridge, MA, USA), which were sensitized 
with 100 µL of monoclonal antibody and incubated 
for 18 h at 4°C. Subsequently, in order to prevent 
nonspecific bindings, the plates were blocked 
with 300 µL of 2% BSA and incubated for 2 h 
at 37°C. After blocking, sample and standards 
diluted in PBS were added at 100 µL/well. Two 
wells were filled only with PBS for use as a blank. 
The plates were incubated for 18 h at 4°C.
After incubation, we added 100 µL 
of biotinylated conjugated antibody at a 
pre-established concentration, and the plates 
were incubated for 3 h at 37°C. Subsequently, 
we added 100 µL of streptavidin-HRP (1:250; 
R&D Systems, Minneapolis, MN, USA) to each 
well, and the plates were incubated for 30 min 
at 37°C. At each step, the plates were washed 
six times in wash buffer (PBS and Tween 20).
For color development, we added 100 µL 
of developer (hydrogen peroxide and 
tetramethylbenzidine) to each well, and the plates 
were incubated for 5 or 60 min, depending on 
the cytokine, at 37°C. The reaction was stopped 
by the addition of 50 µL of 30% sulfuric acid 
to each well, followed by gentle agitation of 
the plates. The plates were read by an ELISA 
reader (Power Wave; Bio-Tek Instruments Inc., 
Winooski, VT, USA) with a 450-nm filter.
in which the animals were given a subcutaneous 
injection of monocrotaline (Sigma-Aldrich, St. 
Louis, MO, USA; 60 mg/kg) on D0; the left 
pneumonectomy (P) group, in which the animals 
underwent left pneumonectomy 7 days prior to 
D0 and received a subcutaneous injection of saline 
(1 mL/kg) on D0; and the monocrotaline+left 
pneumonectomy (M+P) group, in which the animals 
underwent left pneumonectomy 7 days prior to 
D0 and received a subcutaneous injection of 
monocrotaline (60 mg/kg) on D0. 
The pneumonectomy technique used in the 
present study was as follows:
•	The animals were anesthetized with 2.5% 
isoflurane in an anesthesia chamber, 
anesthesia being maintained throughout 
the surgical procedure.
•	The animals were intubated with a 14-gauge 
Jelco® catheter (Johnson & Johnson, São 
José dos Campos, Brazil) and coupled to 
a Harvard rodent ventilator (model 683; 
Harvard Apparatus Co., South Natick, MA, 
USA), RR being maintained at 80 breaths/min 
and tidal volume being maintained at 
10 mL/kg of body weight.
•	The animals were placed in the left lateral 
decubitus position, the left infra-axillary 
region was shaved, and, subsequently, a 
3-cm incision was made between the fourth 
and fifth intercostal spaces, running parallel 
to the spaces.
•	The skin, subcutaneous cellular tissue, and 
intercostal muscle planes were sectioned 
until the thoracic cavity was reached, at 
which point the retractor was placed between 
the ribs.
•	The left lung was freed from its ligaments 
and subsequently drawn out of the cavity.
•	After en bloc ligation of the hilum with 2-0 
cotton sutures, the left lung was sectioned.
•	The muscle planes were closed with 
continuous 3-0 nylon sutures (Ethicon, 
São Paulo, Brazil), and the skin was sutured 
with the same suture material.
The analyses were performed 28 days after the 
injection of monocrotaline or saline. After deep 
sedation with xylazine hydrochloride (0.3 mg/kg, 
i.p.; Rompun®; Bayer, Leverkusen, Germany) 
and ketamine hydrochloride (10 mg/kg, i.p.; 
Ketalar®; Pfizer, New York, NY, USA), the animals 
were weighed. Hemodynamic measurements 
were performed, being followed by euthanasia 
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The IL-1 levels were significantly higher in P, 
M, and M+P rats than in control rats (Figure 4A). 
Although the PDGF levels were also different 
among the groups (p = 0.049), our post hoc 
analysis did not allow us to determine the 
significance of the differences (as it did for the 
IL-1 levels); nevertheless, the distribution of the 
data suggests that the patterns are the same 
(Figure 4B).
Although survival was significantly lower 
in M and M+P rats than in control and P rats 
(p < 0.05), there were no differences between 
M and M+P rats (Figure 5).
Discussion
Our study showed that both the monocrotaline 
model and the model combining monocrotaline and 
increased blood flow produced by pneumonectomy 
induce PAH in rats. Analogously and consequently, 
we observed that RV weight and the index of 
RV hypertrophy were higher in M+P rats than 
in M rats, as well as being higher in M and M+P 
rats than in control and P rats.
It is of note, however, that the index of RV 
hypertrophy (RV/LV+IS ratio) does not represent 
PAH in an absolute sense, because monocrotaline 
can also have a direct effect on the heart.(21) 
Nevertheless, the finding of similar LV weights 
in the different groups does not suggest the 
presence of monocrotaline-induced cardiac 
abnormalities in our study.
The M and M+P rats showed no differences 
in medial area when compared with each other. 
For histological quantification, five different 
randomly selected fields were examined 
(magnification, ×400) after the tissue had 
been stained with Miller’s stain, which allows 
the visualization of elastic fibers. For this 
quantification, we used an image analysis system 
(Carl Zeiss; MicroImaging GmbH, Göttingen, 
Germany) and AxioVision 40 version 4.7.1.0 
software, 2006-2008 (Carl Zeiss Imaging 
Solutions GmbH, Jena, Germany), which 
allows quantitative geometric and quantitative 
densitometric measurements. Specific thresholds 
were established for each slide. The histological 
findings are expressed as area (µm2).(28)
The objective of the survival protocol, with 
40 rats also divided into control, P, M, and M+P 
rats, was to investigate differences in survival 
among the models. The animals were followed 
for 45 days, and the date of death of each rat 
was recorded. All of the remaining animals were 
sacrificed on day 45.
For the statistical analysis, ANOVA with post 
hoc Bonferroni correction was used in order 
to compare continuous variables among the 
groups. Proportional variables were analyzed 
by the chi-square test or Fisher’s exact test, as 
appropriate. Values of p < 0.05 were considered 
significant.
To estimate survival over time, we used the 
Kaplan-Meier method, the survival curves being 
compared by the log-rank test.
Results
Invasive hemodynamic measurements revealed 
that M and M+P rats developed PAH, whereas 
control and P rats did not (Figure 1).
As can be seen in Figure 2A, the RV weight 
was significantly higher in the rats that developed 
PAH (i.e., M and M+P rats) than in those that 
did not (i.e., control and P rats), as well as being 
significantly higher in M+P rats than in M rats. 
There were no differences among the groups 
regarding LV+IS weight (Figure 2B); this caused 
the index of RV hypertrophy (RV/LV+IS ratio) to 
be significantly higher in M+P rats than in those 
in the remaining groups (Figure 2C), similarly 
to the distribution of RV weight.
The medial area was significantly larger in M 
and M+P rats than that in control rats (p = 0.013; 
Figure 2D). There was no intimal proliferation 
in M or M+P rats (Figure 3).
Figure 1 - Comparison of control (C), 
monocrotaline (M), pneumonectomy (P), and 
monocrotaline+pneumonectomy (M+P) rats regarding 
mean pulmonary artery pressure (mPAP) in mmHg. 
*p < 0.001.
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analyze isolated vascular material.(15) This means 
that any inflammatory phenomenon occurring 
in the lungs is reflected in the methodology 
employed, a factor that constitutes a limitation 
of the methodology.
The experimental models of PAH studied do 
not mimic human PAH closely enough. This is due 
to several factors, among which is the speed of 
disease onset, which occurs over years in humans 
but in weeks in rats. It is therefore logical to 
think that the pathophysiological mechanisms 
are different.(21) Consequently, other models, such 
as the model combining monocrotaline injection 
and increased pulmonary blood flow produced by 
systemic-pulmonary shunts or pneumonectomy, 
have been studied.(22-24)
In 1996, Tanaka et al.(22) tested the hypothesis 
that, by raising pulmonary artery blood pressures 
to systemic levels, the effects of monocrotaline 
on pulmonary circulation could be increased. The 
authors found that the creation of a subclavian-
However, when compared with control rats, M 
and M+P rats showed significantly larger areas 
(p = 0.013), which confirmed that the two models 
produce pathological changes typically caused by 
PAH. Control and P rats showed no significant 
differences in medial area. One important finding 
is that there was no intimal proliferation in any 
of the groups, which is at odds with the findings 
of other studies.(23,29)
Regarding inflammatory markers, IL-1 levels 
were significantly higher in P, M+P, and M rats 
than in control rats, and a similar pattern was 
found for PDGF levels. This demonstrates that 
surgical manipulation alone increases the levels 
of these inflammatory markers, which limits their 
use in the comparison of the models, although 
it has been demonstrated that these markers are 
increased in individuals with PAH.(17,30) However, 
it is of note that, in our study, the levels of these 
markers were measured in whole lung samples, and 
no microdissection technique was used in order to 
Figure 2 - Comparison of control (C), monocrotaline (M), pneumonectomy (P), and monocrotaline+pneumonectomy 
(M+P) rats. In A, right ventricle (RV) weight in g, *p < 0.001; in B, left ventricle plus interventricular septum 
(LV+IS) weight in g; in C, the RV/LV+IS ratio, *p < 0.001; in D, medial area in µm2, *p = 0.013.
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(at least not in large blood vessels), even when 
the animals were submitted to systemic pressures.
In a subsequent study,(23) left pneumonectomy 
was followed by injection of monocrotaline. The 
authors of that study found intimal lesions in 
distal pulmonary arteries, a finding that was 
pulmonary artery anastomosis in rats, with 
subsequent injection of monocrotaline, led to 
intimal lesions in large pulmonary arteries. The 
authors demonstrated that, in the absence of 
endothelial injury, there was no vascular remodeling 
Figure 3 - Sample images of histological sections of the media of acinar arterioles (magnification, ×400). C: 
control group; M: monocrotaline group; P: pneumonectomy group; and M+P: monocrotaline+pneumonectomy 
group.
Figure 4 - In A, IL-1 levels in pg/mL, *p < 0.05; in B, PDGF levels in pg/mL, *p = 0.049. C: control group; 
M: monocrotaline group; P: pneumonectomy group; and M+P: monocrotaline+pneumonectomy group.
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employed in the two studies were the same. In 
older rats, postpneumonectomy lung growth is 
less pronounced, as are the inflammatory effects 
of monocrotaline. Therefore, in the study by 
White et al., the observed phenomena might 
be due to compensatory lung growth following 
pneumonectomy.(22,29)
Although we found no significant differences 
between M+P and M rats regarding hemodynamic 
changes or medial thickness, we found that RV 
hypertrophy was greater in M+P rats (Figure 2). 
This finding alone does not allow us to conclude 
that the monocrotaline+pneumonectomy model 
is more severe than is the monocrotaline model, 
because survival was the same. No author had 
tested the difference in survival among the various 
models. We believe that this is the parameter 
that should be used for determining the actual 
severity of the disease produced by experimental 
models.
We can conclude that the results of the 
comparison between the monocrotaline model 
and the model combining monocrotaline and 
increased blood flow do not allow us to state 
that one is definitely superior to the other and 
therefore recommend one over the other as 
the standard for future studies. Because of its 
ease of use, the monocrotaline model is still 
more widely employed, despite its limitations 
in mimicking the pattern seen in human PAH, 
as was confirmed in our study. Nevertheless, 
studies whose primary objective is to evaluate RV 
hypertrophy can benefit from the combination 
of monocrotaline and increased blood flow.
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